...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Frontiers in Medicine >Noninvasive Ventilation in Patients With COVID-19-Related Acute Hypoxemic Respiratory Failure: A Retrospective Cohort Study
【24h】

Noninvasive Ventilation in Patients With COVID-19-Related Acute Hypoxemic Respiratory Failure: A Retrospective Cohort Study

机译：Covid-19相关急性低氧血症呼吸衰竭患者的非侵入性通风：回顾性队列研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Noninvasive ventilation (NIV) has been used to alleviate hypoxemia and dyspnea, but there is no consensus on the application of NIV in patients with coronavirus disease 2019 (COVID-19). Some staff use NIV as the rescue therapy which might lead to the adverse outcomes. This study was to identify early factors associated with intubation to help the medical staff select appropriate patients for receiving NIV treatment. Methods: Patients with laboratory-confirmed COVID-19 who were treated with NIV in emergency department or ICU of the Third People's Hospital (the only designated hospital for treating COVID-19 in Shenzhen) between January 1 and August 31, 2020, were retrospectively analyzed. Results: Thirty-nine patients with COVID-19 treated with NIV were included; of them, 16 (41%) received endotracheal intubation and 3 (8%) died. Significant differences were observed between intubated and non-intubated patients in PaO 2 /FiO 2 before NIV initiation, hospitalization duration, NIV as the rescue therapy, and PaO 2 /FiO 2 of ≤200 mmHg after 1–2 h of NIV initiation. Notably, 1–2 h after NIV initiation, a PaO 2 /FiO 2 of ≤200 mmHg (odds ratio [OR], 9.35; 95% confidence interval [CI], 1.84–47.62; P = 0.007) and NIV as the rescue therapy (OR, 5.43; 95% CI, 1.09–27.12; P = 0.039) were the risk factors for intubation. Conclusions: In patients with COVID-19-related acute hypoxemic respiratory failure receiving NIV, close attention should be paid to PaO 2 /FiO 2 after 1–2 h of NIV initiation. Also, using NIV as rescue therapy should draw our awareness that it might delay escalation of respiratory support and lead to adverse outcomes.
机译：简介：非侵入性通风（NIV）已被用于缓解低氧血症和呼吸困难，但没有关于NIV在2019年冠状病毒疾病患者中的应用共识（Covid-19）。一些员工使用NIV作为救援疗法，可能导致不利的结果。本研究是识别与插管相关的早期因素，以帮助医务人员选择合适的患者接受核育效果。方法：在2020年1月1日至2020年1月31日至2020年1月31日期间，在4月1日至2020年8月31日在2020年1月1日至2020年1月31日期间，在急诊部门或ICU治疗的患有实验室证实的Covid-19患者。结果：包括NIV治疗的Covid-19患者;其中，16（41％）接受了气管插管，3（8％）死亡。在NIV启动前的PAO 2 / FIO 2中的插管和非插管患者之间观察到显着差异，在NIV启动1-2小时后PAO 2 / FIO 2的PAO 2 / FIO 2≤200mmHg。特别是，NIV发芽后1-2小时，PAO 2 / FIO 2≤200mmHg（差距[或]，9.35; 95％; 95％置信区间[CI]，1.84-47.62; P = 0.007）和亡血作为救援治疗（或5.43; 95％CI，1.09-27.12; P = 0.039）是插管的危险因素。结论：患有Covid-19相关急性低氧呼吸呼吸衰竭的患者接受NIV，在NIV启动1-2小时后，应密切关注PAO 2 / FIO 2。此外，使用核育救援疗法应该提出我们可能会推迟呼吸支持的升级并导致不利结果的意识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号